Merck has been active in dealmaking recently completing its acquisitions of ArQule and Themis.
Drugmakers including Novartis, Roche Holding and Bristol-Myers Squibb have snapped up makers of gene therapies because they offer potential to cure a wide range of often-rare diseases by replacing or repairing errors in the body’s instruction manual.
M&A Wrap: Q3 Rebound, Bristol-Myers, Monroe Capital, Avante Capital, MyoKardia, Alibaba, Greenbriar, Uber, Thoma Bravo
Bristol Myers buys heart drug developer. Lending executives including Monroe's Theodore Koenig and Avante's Jeri Harman talk about M&A bouncing back. Greenbriar invests in Uber's logistics arm.
Expanding Bristol-Myers’s lineup of heart drugs would help the maker of Opdivo for cancer diversify beyond oncology, an area where much of the industry has focused in recent years.